Illustrative only. Not actual size. Contains decitabine and cedazuridine.
RESPONSES SHAPED BY A
POWER
FULL
ORAL HMA TREATMENT
RESPONSES SHAPED BY A
POWER
FULL
ORAL HMA TREATMENT
Illustrative only. Not actual size. Contains decitabine and cedazuridine.
Help patients living with AML or MDS, including CMML,
with INQOVI—an oral HMA therapy with proven results
regardless of treatment setting1
Oral vs IV or SC options
Patients with AML or MDS who have been prescribed IV or SC HMA options may face significant treatment challenges, show suboptimal persistence, and prefer oral options.2-10
INQOVI + venetoclax was evaluated as the only all-oral regimen for patients with newly diagnosed AML1,11,12*
INQOVI was evaluated as the only oral HMA therapy for patients with MDS and CMML1,7,13
*In patients 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.1
A demonstrated safety profile for patients with AML or MDS, including CMML1,7,11
INQOVI + venetoclax demonstrated a safety profile consistent with the known safety profiles of both agents, and INQOVI alone demonstrated a safety profile similar to IV decitabine.1,7,11
AML=acute myeloid leukemia; AR=adverse reaction; CMML=chronic myelomonocytic leukemia; CR=complete remission; CRh=complete remission with partial hematologic recovery; HMA=hypomethylating agent; IV=intravenous; MDS=myelodysplastic syndromes; SC=subcutaneous.
References: 1. INQOVI [package insert]. Princeton, NJ: Taiho Oncology, Inc.; 2026. 2. Haumschild R, Kennerly-Shah J, Barbarotta L, Zeidan AM. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a multidisciplinary review. J Oncol Pharm Pract. 2024;30(4):721-736. 3. Jensen CE, Heiling HM, Beke KE, et al. Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens. Haematologica. 2022;108(4):1006-1014. 4. Zeidan AM, Salimi T, Epstein RS. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials? Future Oncol. 2021;17(36):5163-5175. 5. Zeidan AM, Jayade S, Schmier J, et al. Injectable hypomethylating agents for management of myelodysplastic syndromes: patients’ perspectives on treatment. Clin Lymphoma Myeloma Leuk. 2022;22(3):e185-e198. 6. Petzer V. Oral therapies for unfit patients with acute myeloid leukemia. memo. 2025;18:341-344. 7. Garcia-Manero G, McCloskey J, Griffiths EA, et al. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024;11(1):e15-e26. 8. Zeidan AM, Wang R, Wang X, et al. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Adv. 2020;4(10):2192-2201. 9. Delmas A, Batchelder L, Arora I, et al. Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia. Front Oncol. 2023;13:1160966. 10. Zeidan AM, Tsai J-H, Karimi M, et al. Patient preferences for benefits, risks, and administration route of hypomethylating agents in myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2022;22(9):e853-e866. 11. Data on file. Taiho Oncology Inc., Princeton, NJ. 12. Pharmacokinetics, safety, and efficacy of ASTX727 in combination with venetoclax in acute myeloid leukemia (AML). ClinicalTrials.gov identifier: NCT04657081. Updated December 8, 2025. Accessed May 12, 2026. https://clinicaltrials.gov/study/NCT04657081 13. Zeidan AM, Perepezko K, Salimi T, Washington T, Epstein RS. Patients’ perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms. Ther Adv Hematol. 2024;15:1-11.